Find out about the work of our project manager, Dr. Julie Le Faouder, expert in proteomics and peptidomics. In this interview, she tells us more about the exciting research projects she is carrying out on the characterisation of bioactive peptides obtained from marine by-product hydrolysates, and her role in “VIPP” scientific programme.
Julie, you are the peptidomics project manager for Abyss Ingredients. What does your job involve?
I have 15 years of experience working in biomolecular analysis, 12 of which in proteomics for the health sphere, based in a university laboratory. My job as project manager for Abyss Ingredients is to identify and characterise specific bioactive peptides obtained from marine hydrolysates.
My research focuses on characterising the bioactive peptide sequences in our Peptidyss product which play a role in the management of sleep, stress and burn-out.
This study is part of the VIPP research programme sponsored by Abyss Ingredients. This 100% Breton collaborative research project is backed and funded by the ERDF (European Regional Development Fund) and Région Bretagne organisation. Working with expert partners and universities, academics and manufacturers makes this ambitious project particularly attractive to me. It forms part of the drive to improve the quality of Abyss products, particularly Peptidyss, recognised today as being beneficial for stress management. The first results of this venture, launched in 2019, should be available by 2021.
You talk about bioactive peptides, what is it?
Julie, you are expert in peptidomics. Could you tell us more about this approach?
Can you explain how you technically proceed?
Hydrolysed food proteins are complex blends which generally contain hundreds of peptides of differing chain lengths and relative abundance, which makes it difficult to detect all the peptides. To improve the analysis, protein hydrolysates are often fractionated using different methods (ultrafiltration, hydrophobic, ion exchange or size exclusion, high-performance liquid chromatography (HPLC)) before peptidomics analysis takes place.
So the stage prior to characterising the bioactive peptide sequences involves separating the sample of complex marine hydrolysate in order to isolate biologically active peptides, i.e. the ones that have a physiological activity in our bodies. To do this, in vitro efficacy tests are performed on the different fractions.
Then the peptides from the most active fractions are characterised using the peptidomics approach. The outcome may range from general profiling of the peptides contained in these fractions to the identification and validation of specific bioactive peptides. The second activity is what we are aiming to achieve in our VIPP project.